Letter from the Editor


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 2978.

Product Description

Patient-centricity, patient engagement, patient focus — no matter what you call it — is gaining increasing attention in and outside of the industry. Forbes’ contributor Dave Chase recently wrote an article on “The 7 Habits of Highly Patient Centric Providers.” In his article, he cites that one of the transformative organizations pushing for change is Oliver Wyman’s Health Innovation Center. The center recently published a paper entitled The Volume-to-Value Revolution with the input of an advisory board of CEOs ranging from large public companies to emerging companies. And in that paper, authors Tom Main and Adrian Slywotzky make the case that new patient-centered population health models will cause more than $1 trillion of value to rotate from the old models to the new and create more than a dozen new $10 billion…

Their Word…

Denise Myshko
Managing Editor

The first product has been filed for approval under the new law that created a biosimilar ­regulatory path; this pending ­approval is expected to change the biotechnology market.

Robin Robinson
Senior Editor

Pharma is beginning to embrace exciting new tools and strategies in order to connect with the digital patient, as well as bring more value beyond the pill.

Kim Ribbink
Features Editor

Given its strong healthcare system and modern ­technologies in larger cities such as Santiago, Chile is certainly poised to grow with the market.

in October 2014
> Collaboration: Real Knowledge Sharing
> In the Pharmacy
> Academic Research Centers
> Career Tools
> Investigator Training
> C-Suite — Specialty Pharma
> Market Focus — Columbia
> Showcase Feature — Supply Chain & Logistic Management
> Showcase Feature — Patient Solutions

The forum for the industry executive
Volume 14 • Number 8

Publisher    Lisa Banket
Editor    Taren Grom
Creative Director    Marah Walsh

Managing EDitor
Denise Myshko

Senior EDitor
Robin Robinson

features EDitor
Kim Ribbink

design associate
Ariel Medel

Director of Sales
Cathy Tracy

national account manager
Suzanne Besse

Daniel Limbach

Kathy Deiuliis

Copyright 2014
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Fourteen, Number Eight

PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O.?Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O.?Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail:

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail:

Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O.?Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail:

Send your letters to feedback@pharma­ Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC.